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A B S T R A C T
Aim: To investigate the effect of a macro-nutrient preload (Inzone Vitality) on blood glucose levels and
pregnancy outcomes of gestational diabetes. The preloadmethod involves the ingestion of a smaller amount
of a macronutrient composition half an hour before regular meals. The hypothesis was that preload treat-
ment will reduce postprandial glycemia in gestational diabetes.
Methods: Sixty-six diagnosed cases of gestational diabetes were randomly selected from gynecology and
obstetrics outpatient clinic at Xinqiao Hospital in Chongqing. The patients were divided into an inter-
vention group (33 cases) and a control group (33 cases), according to odd–even numbers of the random
cases. The intervention group was treated with a macro-nutrient preload given 0.5 h before regular meals
and the control group was given a comparative treatment consisting of a milk powder with similar energy
content. The two groups were studied until delivery and the measured parameters included fasting blood
glucose (FBG), 2-hour postprandial blood glucose (2h-PBG), delivery mode and neonatal birth weight.
Results: The two groups showed no differences in FBG or 2h-PBG before the nutritional intervention. FBG
and 2h-PBG after intervention and before delivery were signiﬁcantly lower in the intervention group,
treated with the macro nutrient preload compared to the control group (P < 0.01). Changes in FBG and
2h-PBG before and after the intervention were investigated and the difference in the intervention group
was signiﬁcantly greater than corresponding values in the control group (P < 0.05, P < 0.01). The neona-
tal birth weight and delivery mode was not signiﬁcantly different (P > 0.05).
Conclusion: A macro-nutrient composition, used as a preload, is effective in controlling FBG and PBG of
gestational diabetes.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Gestational diabetes mellitus (GDM) refers to glucose toler-
ance abnormalities of varying degrees that occur or are ﬁrst
discovered during pregnancy. It accounts for 80–90% of diabetes in
pregnancy and includes gestational impaired glucose tolerance. In
2007, the Obstetrics Branch of the Chinese Medical Association con-
ducted a nationwide epidemiological study of patients with GDM,
showing that the average prevalence of GDM in China was 6.6% with
a trend of yearly increases, conﬁrmed by a population-based study
in Tianjin 2012, where the prevalence of GDM was 8.1% using the
1999WHO criteria which was further increased to 9.3% if the 2010
IADPSG criteria were used [1]. Women with a history of GDM have
an increased risk of complications during delivery and have a sev-
enfold increased risk of getting diabetes later in life. Likewise, their
offspring have an increased risk at birth and increased risk of dia-
betes and obesity later in life [2]. GDM in itself can cause epigenetic
“programming” of the fetal metabolism [3] and maternal hyper-
glycemia can therefore potentially lead to trans-generational effects
with increased disease risks for the offspring. This adds to the burden
many are facing in the prevention of T2DM and its micro- and
macrovascular consequences. One feature of GDM is that the disease
is often asymptomatic, patients rarely have any symptoms at the
time of diagnosis (often at week 24–28), and an important aspect
of treatment concerns life style changes [4,5]. The screening and
diagnosis of GDM are important as are interventions aiming to reduce
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adverse outcomes during pregnancy, immediately after delivery and
in a long term perspective. A positive screening test must be linked
to a safe and effective method to treat the hyperglycemia and its
feared short and long term consequences.
The need for both preventive and therapeutic measures is now
urgent, where life style changes, most importantly introduction of
healthy diets, are crucial. A prerequisite for the introduction of this
kind of healthy nutrition to the general public is that “Medical Nu-
trition Therapy (MNT)” is evidence based, i.e. has a strong and
undisputable scientiﬁc support. Nutritional therapy can maintain
blood glucose at a normal level and ensure that the mother’s phys-
iological requirements and the fetus’ developmental requirements
are met. Diet control is not only beneﬁcial for controlling mater-
nal weight and improving hyperglycemia, it can also raise the insulin
sensitivity in target tissues [6].
A new method has emerged that meet these requirements, the
so called macro-nutrient preload method, which has been devel-
oped to treat and prevent obesity and type 2 diabetes (T2DM). By
administration of a small load of macro-nutrients at a ﬁxed inter-
val before ameal (30minutes in themajority of studies) the presence
of nutrients in the small intestine induces the release of gut pep-
tides like GLP-1, which slows gastric emptying and improves the
glycemic response to the subsequent meal [7–9].
In a recent study of patients with Type 2 Diabetes (T2DM) the
ingestion of a macro nutrient preload before major meals, signiﬁ-
cantly reduced 2h-PBG, HbA1c, total cholesterol/LDL and CRP at the
end of a 12-week treatment period [10]. The tested macro nutri-
ent preload was a blend of three different protein sources, slow-
release carbohydrates, dietary ﬁbres, omega3/6 fatty acids and other
components. The mode of action of macronutrient preloads is
assumed to be increased satiety, reduced gastric emptying and at-
tenuated postprandial blood sugar response [11]. Based on this study
and previous studies of the macro-nutrient preload method, we hy-
pothesized that the nutritional composition used in the above
mentioned T2DM study (Inzone Preload – a macro-nutrient blend
with low-GI and low calorie content) would reduce postprandial
glycemia in GDM patients when compared to controls consisting
of a regular milk powder. To test this hypothesis, we performed a
controlled clinical study which aimed to explore the potential effects
on blood glucose levels and pregnancy outcomes in women diag-
nosed with GDM for the ﬁrst time.
Subjects and methods
Subjects
We collected 80 patients, 26–38 years old who received a def-
inite diagnosis of GDM at our hospital’s obstetrics and gynecology
outpatient clinic from November 2013 to May 2014. Subject
inclusion criteria: (1) deﬁnite diagnosis of GDM at our hospital’s
outpatient clinic; (2) voluntarily signed the informed consent form;
(3) deemed suitable for treatment by a dietitian. Subject exclu-
sion criteria: (1) continuously positive for urine ketone bodies; (2)
fasting blood glucose and postprandial blood glucose remaining
high after 1–2 weeks of nutritional intervention. In line with our
clinical experience, patients with fasting blood glucose >6.1 mmol/L
and two-hour postprandial blood glucose >11.1 mmol/L after 1–2
weeks of nutrition intervention will be treated with insulin to
reduce blood glucose; (3) gestational hypertension, and severe
hepatic or renal dysfunction; (4) refusing to follow the dietitian’s
instructions regarding diet. During the study all of the GDMwomen
only used diet to control blood sugar and were not in need for
any pharmacological treatment. Ethical permission was obtained
from the Third Military Medical University Ethics Committee (no
ChiCTR-IoR-14005522).
Diagnostic criteria
Patients who met any of the following criteria were diagnosed
with GDM: (1) Fasting blood glucose ≥5.1mmol/L; (2) blood glucose
≥10.0 mmol/L one hour after a 75-g OGTT performed after fasting
for eight hours at 24–28 weeks of gestation; (3) blood glucose
≥8.5 mmol/L two hours after an OGTT. These different criteria has
the following distribution: a total of 30 subjects with fasting blood
glucose ≥5.1 mmol/L in line with the GDM diagnostic criteria (16
subjects in the intervention group, 18 in the control group); a total
of 43 subjects in weeks 24–28 of pregnancy with blood glucose
≥10 mmol/L one hour after administration of 75 g OGTT″ (23 sub-
jects in the intervention group, 20 in the control group); and a total
of 45 subjects with blood glucose ≥8.5 mmol/L two hours after ad-
ministration of OGTT″ (23 subjects in the intervention group, 22 in
the control group).
Methods
Randomized design where one group received a macro nutri-
ent preload (intervention) and the other group received a comparator
consisting of a milk powder (control). All patients were numbered
by the time of hospitalization and grouped by the random numbers,
namely, intervention group (macro nutrient preload) by odd number
and control group by even number, each with 40 cases. During the
experiment, 7 cases from each group were canceled due to hyper-
glycemia or failure to follow the dietitian’s instructions, thus 33 cases
from each group were selected to participate in the study (Fig. 1).
A total of 6 subjects were excluded due to excessive hyperglyce-
mia, 2 subjects in the intervention group and 4 subjects in the control
group. The remaining 8 subjects did not comply with the instruc-
tions of the nutritionist or moved to another part of the country.
Subjects that were excluded due to excessive hyperglycemia were
thosewho had fasting blood glucose >6.1mmol/L and two-hour post-
prandial blood glucose >11.1 mmol/L after 1–2 weeks of nutrition
intervention in blood glucose taken by nurses from the clinical lab-
oratory at Xinqiao Hospital once per week after starting on nutrition
intervention. These patients were treated with insulin to reduce
blood glucose, in line with the clinical experience of our hospital’s
gynecologist, and were considered withdrawn from observation.
The mean age of intervention group was 32.7 ± 4.9 years and the
one of the control group was 30.8 ± 4.7 years, showing no signiﬁ-
cant difference (P > 0.05). In this study the patients were randomly
selected to be given intervention or control treatment and the sub-
jects were not aware if they received intervention or comparator
treatment. The project leaders were aware of which treatment that
was given.
Intervention measures: a record consisting of basic personal in-
formation, health status and pregnancy outcomewas kept by Xinqiao
Hospital where also follow-up visits were conducted. All subjects
in each group were given nutritional education, and were given
dietary recommendations; diets were formulated according to the
daily energy demand of GDMpatients up to 30–38 kcal/kg ideal body
weight and was adapted to the actual weight of patients, weight
increment in pregnancy, age, physical activities, family history, etc.
These mainly consisted of six meals per day, consisting of three
regular meals and three snacks. For the intervention group, a mac-
ronutrient preload nutrition powder (Inzone Vitality; imported from
Sweden, original packing, provided by Tianjin Health Promotion
Technology Co., Ltd.) was given as three pre-meals 30minutes before
ordinarymeals (meal timeswere: 7:30, 11:30, and 17:30). The Inzone
Vitality product consists only of natural food ingredients (pea-
protein, whey protein, egg albumin, Ω 3/6 fatty acids, whole eggs,
apple, rosehip and sugar beet ﬁber). Each serving of Inzone Vital-
ity (18 gram) contains 7.6 g protein, 1.8 g fat (saturated and
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unsaturated fat are 0.6 g and 1.2 g respectively), 1.6 g ﬁber and 5.2 g
carbohydrates, which provided 71 kcal energy (Indevex Biotech,
Sweden) and a low Glycemic Index, GI. Each sachet containing 18 g
was dissolved in water at ambient temperature before use. The
patient directly drank in a single draft the entire preparation made
by mixing the powder with 150 mL water. After drinking the prep-
aration, the patient drank another 100 mL water and then started
a regular meal half an hour later.
The control group was given a comparator consisting of a milk
powder for pregnant women (Nestle Ange milk powder (https://
www.nestle.com.cn/)). The product was produced in Heilongjiang,
China (QS serial number 2300 0510109) and had the following com-
position: 18 g per serving, energy 73 kcal, protein 3.5 g, fat 1.1 g
carbohydrates 11.2 g. Treatment of the control group was given in
accordance with the principles described above for the Inzone Vi-
tality (preload 30 minutes before major meals).
NGC preload was developed to provide a high protein/low car-
bohydrate composition. As a control composition (comparator) we
selected a milk based composition characterized by less protein and
a higher content of carbohydrates. A comparison between preload
and control is shown in Table 1.
Table 1 shows a comparison between intervention treatment i.e.
macro-nutrient preload (Inzone Vitality) and Control (Nestle Ange
milk) in terms of protein, fat and carbohydrate contents. The table
lists the amount (g) in each 18 g serving. Numbers in parenthesis
shows the percent content per serving.
In addition to nutritional treatment, the remaining treatment for
the two groups was subjected to the same or similar modality. In-
tervention for each patient was concluded after discharge following
delivery. The duration of treatments was for the intervention group
65.3 ± 8.2 days and for the control group 65.9 ± 8.6 days, i.e. no sig-
niﬁcant difference between the two groups.
Methods of evaluation: primary outcomemeasurement was two-
hour postprandial blood glucose levels following a standardizedmeal.
Secondary outcome comparisons were made with fasting blood
glucose measurements. Additional data were collected and in-
cluded delivery method, neonatal birth weight and Apgar score.
Instruments and tools
Adult weight and height were measured using the RGZ120 body
scale (weight calibrated to ±0.2 kg; height calibrated to ±0.5 cm)
manufactured by the Auxin Scales Factory inWuxi City, China. Neo-
natal birth weight was measured using the Life Sense neonatal scale
(calibrated to ±0.05 kg). Blood glucose was tested using the Roche
Accu-Chek Active II. Diets were formulated using Nutrition System
of Chinese Traditional Medicine Combining Western Medicine
(NCCW) MX1 (version: V11.0) software. Patients had their blood
glucose tested once every week after nutritional intervention, by
nurses from the clinical laboratory at Xinqiao Hospital. In line with
clinical experience, the gynecologist requires patients with fasting
blood glucose >6.1mmol/L and two-hour postprandial blood glucose
>11.1 mmol/L after 1–2 weeks of nutrition intervention be treated
with insulin to reduce blood glucose.
Fasting blood glucose is blood glucose taken before the ﬁrst meal
of the day after rising at 7:00 in the morning, and having taken the
ﬁnal meal of the previous day at 21:00.
Statistical methods
A power calculation (0.8) was carried out using a signiﬁcance
level of 0.025, SD of 1.29 and a difference in means of 1 mmol/L,
for the 2 h post prandial glucose level between the intervention group
(macro-nutrient preload) and the control group. This resulted in that
minimally 56 patients should enter this two treatment (interven-
tion and control) parallel-design study. Data from the subjects in
this investigation (n = 66) were entered and saved in an Excel soft-
ware system. SPSS18.0 software was used for statistical analysis and
charting. Quantitative data were analyzed using a two-tailed t-test
after normality testing. Qualitative data were analyzed using a χ2
test. The level of statistical signiﬁcance was P < 0.05.
Results
The results in Fig. 2 show no signiﬁcant difference between the
groups with respect to fasting blood glucose and postprandial blood
glucose before intervention. One group of GDM patients were sub-
sequently treated with the macro-nutrient preload for an average
of 65 days and this group was compared to a similar sized control
group treated with a comparator for a similar time period. As shown
Eligible (108)
Excluded (28)
Under 26 or over 38 years of age
(10)
Not meeting inclusion criteria (16)
Random allocation (80)
Intervention group (40) Control group (40)
Lost to follow-up
Delivered in other hospital 
or region (2)
Stopped intervention
Need insulin treatment to 
lower blood glucose (2)
Non-compliance with 
nutritionist (3)
Included in analysis (33) Included in analysis (33)
Lost to follow-up
Delivered in other hospital 
or region (1)
Stopped intervention
Need insulin treatment to 
lower blood glucose (4)
Non-compliance with 
nutritionist (2)
Figure 1. Depicts the number of patients that were enrolled to take part in the clin-
ical testing of macronutrient preload. The diagram shows the number of patients
not meeting inclusion criteria as described in the text. The selected patients, after
meeting inclusion criteria, were divided into an intervention group (macro nutri-
ent preload) and a control group where each consisted of 40 individuals. Thirty-
three subjects in each group concluded the investigation. The reasons for drop-out
are listed in the Figure.
Table 1
Comparison between macronutrient preload and control comparator
NCG preload Control
Protein 7.6 g (42%) 3.5 g (19%)
Fat 1.8 g (10%) 1.1 g (6.1%)
Carbohydrates 5.2 g (28%) 11.2 g (62%)
Energy 71 kcal 73 kcal
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in Fig. 2, there was a signiﬁcant difference between the groups with
respect to fasting blood glucose and postprandial blood glucose after
the intervention and before delivery. The preload treated group (in-
tervention group) had a signiﬁcantly reduced (P < 0.01) blood glucose
level compared to controls and this was also the case with post-
prandial glucose levels. This demonstrates that an Inzone preload
is beneﬁcial for the control of postprandial blood glucose in pa-
tients with gestational diabetes.
Table 2 shows that mean change in fasting blood glucose was
more pronounced in the control group compared to the macro-
nutrient preload treated group (P < 0.05). This demonstrates that
Inzone Vitality is beneﬁcial for controlling fasting blood glucose in-
crements. The change in two-hour postprandial blood glucose,
measured before and after nutritional intervention, was de-
creased in both groups, but the decrease was more pronounced in
the intervention (macro-nutrient preload) group (P < 0.01). This dem-
onstrates that Inzone preload treatment signiﬁcantly improves
postprandial glucose levels.
Neonatal birth weights were as shown in Table 3. There was a
trend toward a reduced birth weight in macro-nutrient preload
treated GDM patients, but this difference was not statistically sig-
niﬁcant (P > 0.05). Delivery was carried out by Cesarean section in
a majority of cases (60%) in both groups. Table 3 shows that there
were no signiﬁcant differences between the two groups with respect
to the number of Cesarian sections or in the neonatal Apgar score.
Discussion
The incidence of GDM is increasing year by year and has become
themost common pregnancy/delivery complication, with health risks
for the mother and the child [12]. Our study shows that ingestion
of a speciﬁed blend of nutrients before major meals, the macro nu-
trient preload method, improves gestational hyperglycemia. This
method thereby has the potential to decrease the risks associated
with GDM for themother and the fetus/newborn child. To our knowl-
edge this is the ﬁrst study of this method in gestational diabetes,
and also the ﬁrst controlled study using a speciﬁc diet regimen to
GDM patients in general.
Normal pregnancy is associated with a progressive increase of
maternal insulin resistance and hyper-insulinemia from the in-
creased insulin secretion from the mother. This is vital for delivery
of nutrients to the fetus and fetal growth. Insulin sensitivity is either
normal or slightly increased during early gestation (<20 weeks),
whereas it decreases during mid to late pregnancy, with compen-
satory increases in maternal insulin secretion. It is for this reason
that the body’s fasting blood glucose and postprandial blood glucose
exhibit a tendency to be increased as pregnancy progresses [13].
Glucose intolerance in pregnancy increases risks for both mother
and child, such as higher rates of preeclampsia, operative deliver-
ies, macrosomia and birth injury. High maternal glycemia results
in increased fetal insulin production, which is considered to be the
main driver of large for gestational age, LGA, and macrosomia. Hy-
perglycemia in pregnancy and neonatal adiposity has also been
linked to increased subsequent childhood obesity and early adult-
hood T2DM. How the intrauterine environment confers higher risk
is not fully understood, but data from animal studies suggest that
epigenetic processes modulate gene transcription in utero.
Diet control is fundamental in both preventing and treating GDM
[14–17]. In China, insulin therapy is only considered for those pa-
tients in whom blood glucose control is inadequate after 1–2 weeks
of diet control [18]. Healthy nutrition ensures normal develop-
ment of the fetus and controls the mother’s postprandial blood
glucose and weight gain during pregnancy within an ideal range.
In addition, performing suitable exercise can increase the body’s sen-
sitivity to insulin, which helps lower blood glucose in GDM patients.
Thus, life style measures lower the risks for developing GDM and
its consequences like hyperglycemia, hypoglycemia, ketosis, and other
symptoms that adversely affect the mother and child [19]. In the
present study, GDM patients underwent nutritional education and
were informed of suitable food choices. A suitable diet was also for-
mulated for each mother. These diets provided the daily intakes and
compositional ratios of energy, protein, fat, carbohydrate, and other
nutrients. In addition, to prevent patients from consuming only single
foods, simple food substitutions were provided. The foods and drinks
that were permitted and those that were not were also explained
to the patients in detail.
In contrast to traditional nutritional therapy, which focuses on
the amount of total energy, macro-nutrients and the amount of car-
bohydrates, the macro-nutrient preload method focus on the
therapeutic potential, with a deﬁnedmode of action. Several studies
suggest that the macronutrient preload can have a vital role in the
care of diabetic patients [7,11,20]. These studies show that a preload
Figure 2. Effect of a macro-nutrient preload on blood glucose before and after in-
tervention in GDM patients. The graph depicts the mean fasting blood glucose (FBG)
and themean 2 h post-prandial blood glucose levels (mmol/L) before and after macro-
nutrient preload treatment. Both control and intervention groups include 33 cases;
error bars indicate one SEM, #P < 0.01.
Table 2
Effect of a macronutrient preload on blood glucose changes in GDM before and after
intervention ( x ± SEM, n = 33)
Group Fasting blood
glucose change
(mmol/L)
2-hour postprandial
blood glucose
change (mmol/L)
Intervention group (n = 33) 0.04 ± 1.19* −3.19 ± 1.48**
Control group (n = 33) 0.62 ± 0.91 −1.74 ± 1.87
* P < 0.05.
** P < 0.01.
Table 3
Effect of a macronutrient preload on birth weight, Cesarian section and Apgar score
Group n Birth
weight, kg
Cesarian
section [n (%)]
Apgar score
10 [n (%)]
Intervention 33 3.33 ± 0.45 20 (60.6) 33 (100)
Control 33 3.44 ± 0.50 21 (63.4) 33 (100)
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of macronutrients signiﬁcantly increases the release of gut hor-
mones which in turn slow gastric emptying, increases the release
of insulin and attenuates the blood glucose response after a meal
– the postprandial blood glucose (PBG).When nutrients interact with
the small intestine, they generate feedback that slows further gastric
emptying and suppresses appetite, via both neural and hormonal
mechanisms. The latter include GLP-1, cholecystokinin (CCK) and
peptide YY (PYY). The small and large intestines also secrete pep-
tides that account for the “incretin” effect – the phenomenon by
which insulin secretion is at least doubled when glucose is given
by the enteral route when compared to an isoglycemic intrave-
nous glucose infusion [21,22]. Several studies have established that
the peak changes in hormone concentration are occurring within
30–60 minutes of preload ingestion, which also is the basis for the
“30 minute rule” in the preload method [7,20].
Themost important result of the preload intervention in our study
is the impact on the postprandial blood glucose 2 hours after the
meals (2h-PBG). Given that nutrients emptying from the stomach
are in the range of 1–4 kcal/min [23] and that people nowadays gen-
erally consume three main meals per day, often with snacks in
between, it is clear that most of the day is spent in the postpran-
dial state, with only a few hours of true fasting before breakfast [24].
The traditional focus on controlling “fasting” blood glucose in the
management of type 2 diabetes is, therefore, often inappropriate.
For the majority with type 2 diabetes, who have relatively good
overall glycemic control like the GDM subjects, postprandial gly-
cemia predominates over fasting blood glucose in contributing to
HbA1c, and a deterioration in postprandial glycemic control pre-
cedes any substantial elevation of fasting blood glucose [25].
Therapies that speciﬁcally target postprandial glycemic excur-
sions are therefore of fundamental importance in preventing the
progression of hyperglycemic conditions like GDM and T2DM and
the emergence of micro- and macro-vascular complications, whose
incidence is related closely to the HbA1c [26]. In the recently updated
ADA/EASD guidelines for managing type 2 diabetes, nutritional strat-
egies to reduce postprandial glycemia are recommended as a ﬁrst
line treatment, and represent the greatest opportunity for optimiz-
ing glycemic control at affordable costs as the healthcare demands
of our society escalate [27].
The strength of this study is the design where a macro-nutrient
preload was compared to a control milk powder with a higher GI.
It is a challenge to ﬁnd a suitable placebo treatment for macro nu-
trient treatments and in the present study we choose regular milk
powder as a comparator but this treatment is likely to exert some
biological effects. A recent, not placebo controlled, study shows that
a 12 week macro-nutrient preload treatment had positive effects
on T2DM patients [10]. Ma et al. demonstrate sustained effects on
glycemia and gastric emptying in T2DM patients following a four
week trial using a protein based preload [20]. The present study
suggest GDM as an indication for macro-nutrient preload treat-
ment and possibly this can be a ﬁrst line therapy to women with
impaired glucose control during pregnancy. Ideally the treatment
should be commenced as early as possible, to prevent the devel-
opment of impaired glucose intolerance to GDMor T2DM, but further
research is necessary for clariﬁcation. There are limitation of the
present study and follow up studies are needed that could e.g.
include a larger number of patients, a comparison with standard
care, more speciﬁc classiﬁcation of GDM, more advanced monitor-
ing of treatment effects, dynamic effects on several metabolic
parameters and effects on GDM patients from other countries.
In summary our study found that macro-nutrient preload treat-
ment has positive effects on GDM.We found that postprandial blood
glucose was signiﬁcantly lower in the intervention group com-
pared to the control group but also that there was a tendency in
control group for a reduced postprandial glucose (Fig. 2). This
indicates that nutritional education and nutritional intervention per
se are beneﬁcial in controlling GDM patients’ postprandial blood
glucose level. With respect to neonatal birth weight and macroso-
mia in our study, there was a trend of decreased birth weight after
macro-nutritional preload intervention, although not signiﬁcant. The
short and long term health effects of the macro-nutrient preload
method for the mother and newborn child need to be further in-
vestigated, including the impact on the risk of developing T2DM for
both mother and child, recurrence of GDM during next pregnancy
and other metabolic consequences.
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